Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253803 | 0.95 | EGFR (0.46) | EGFRGAKFGFR4KDM1A | |
| SCHEMBL30001048 | 0.93 | EGFR (0.45) | EGFRENPP1PDPK1GAKKDM4E | |
| SCHEMBL30000368 | 0.93 | EGFR (0.45) | EGFRENPP1PDPK1GAKKDM4E | |
| SCHEMBL30001229 | 0.93 | EGFR (0.45) | EGFRENPP1PDPK1GAKKDM4E | |
| SCHEMBL30000483 | 0.88 | ENPP1 (0.59) | EGFRENPP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL241727 | 0.87 | EGFR (0.58) | EGFRKDM4EALDH1A1SMN1; SMN2FGFR4 | |
| SCHEMBL5682691 | 0.87 | ENPP1 (0.48) | EGFRENPP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30864339 | 0.87 | ENPP1 (0.48) | EGFRENPP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5678927 | 0.87 | ENPP1 (0.48) | EGFRENPP1KDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8814048 | 0.85 | EGFR (0.56) | EGFRKDM4EALDH1A1SMN1; SMN2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309133-B2 | Nanoparticulate quinazoline derivative formulations | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-11-13 | — | — | US | disclosed |
| EP-1871345-B1 | NANOPARTICULATE ERLOTINIB FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2012-08-01 | — | — | EP | disclosed |
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | ELAN PHARMA INTERNATIONAL, LIMITED | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | KRAS, NRAS, ABL1 | EGFR 80/4885ENPP1 3518/4885PDPK1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.